Sequential CHIR and Activin A Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into definitive endoderm, particularly for generating insulin-producing beta cells for diabetes treatment, are inefficient and unstable, with existing protocols often leading to delayed and less robust induction of SOX17 expression.
Innovation Solution
A method involving a sequential exposure of pluripotent stem cells to CHIR followed by Activin A, where CHIR is used alone for 24 hours without Activin A, induces a significant upregulation of primitive streak markers, leading to an earlier and more pronounced peak of SOX17 expression and efficient definitive endoderm formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional protocols use Activin A and Wnt3a combination for definitive endoderm induction, then DE formation can be achieved, but the protocol is less efficient and SOX17 expression peak is delayed
Solution Approach 1:
The patent segments the differentiation protocol into distinct phases: a priming phase using only CHIR (without Activin A) to establish proper signaling conditions, followed by a DE induction phase. This segmentation allows each factor to act optimally at the right time, improving overall efficiency and accelerating SOX17 expression compared to simultaneous combination protocols.
Solution Approach 2:
The patent applies preliminary action by using CHIR alone in a priming step before adding Activin A for definitive endoderm induction. This preliminary CHIR treatment prepares the cells by inducing primitive streak markers and creating optimal conditions for subsequent DE formation, leading to faster and more efficient SOX17 expression.
2Reliability
If CHIR and Activin A are used together during priming, then DE induction can occur, but protocol stability decreases and efficiency is reduced
Solution Approach 1:
The patent divides the protocol into separate functional segments: a CHIR-only priming segment that ensures stable and reproducible primitive streak formation, followed by an Activin A-containing segment for DE induction. This temporal separation eliminates the instability caused by simultaneous use while maintaining high differentiation efficiency.
Solution Approach 2:
The patent implements preliminary CHIR treatment to stabilize the priming phase before introducing Activin A. This preliminary action creates a stable foundation of primitive streak markers that ensures reproducible and efficient subsequent DE induction, resolving the contradiction between stability and efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a faster, more efficient, and robust differentiation of human pluripotent stem cells to definitive endoderm, with improved SOX17 expression and cell density, outperforming conventional protocols and maintaining protocol stability.
Implementation Method 1
CHIR is a glycogen synthase kinase 3 beta (Gsk3b) inhibitor and a known component of a defined tissue culture medium to maintain mouse embryonic stem cells in the pluripotent state
Implementation Method 2
Induction of DE has been described by the use of Activin A/Nodal with or without the combination of Wnt
Data Source
Figure 1~2A
Figure 2B~2C
Figure 3A
AI summary
The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.